Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

AR-13324 is a small-molecule inhibitor of Rho kinase and a norepinephrine transporter. The objective of this 28-day study was to evaluate the ocular hypotensive efficacy and safety of AR-13324 ophthalmic solution compared with a positive control, latanoprost ophthalmic solution, in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Ophthalmology

Title: Ophthalmology

ISSN (Electronic): 1549-4713

ISSN (Print): 0161-6420

Publication date (Electronic): Feb 2015

Volume: 122

Issue: 2

Affiliations

[1 ] North Bay Eye Associates, Sonoma County, California.

[2 ] Clayton Eye Center, Morrow, Georgia.

[3 ] Aerie Pharmaceuticals, Inc., Bedminster, New Jersey, and Research Triangle Park, North Carolina.

[4 ] PharmaLogic Development, Inc, San Rafael, California. Electronic address: gary_novack@pharmalogic.com.

Article

Publisher Item ID: S0161-6420(14)00760-X

DOI: 10.1016/j.ophtha.2014.08.022

PubMed ID: 25270273

SO-VID: c2dfc35e-ba7f-4756-9377-7e2dad79e9ac

History

Data availability:

Comments

Comment on this article

scite_

Cited by 43

See all cited by

- Version 1